Tag: Biocon Biologics
GENERAL Biocon Arm Secures Positive EMA Opinion For Pertuzumab Biosimilar

Biocon Biologics Ltd, a wholly-owned subsidiary of Biocon Ltd, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation for its Pertuzumab biosimilar, Pebrilzo, for the treatment of HER2-positive breast cancer. The product, available as a 420 mg concentrate solution for […]

CW Bureau · Sep 21, 2026
GENERAL Biocon Biologics Secures Japan Govt Approval For Pegfilgrastim Biosimilar

Biocon Biologics Ltd, a wholly owned subsidiary of Biocon Ltd., has received marketing approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar, strengthening the company’s biosimilars portfolio in the Japanese market. The product is a biosimilar to Neulasta, a pegfilgrastim-based medicine used to reduce the risk of infection associated with […]

CW Bureau · Aug 25, 2026